Novo Nordisk shares rise 7.71% premarket after reporting a 32% increase in Q2 net profit.

Novo Nordisk A/S rose 7.71% in premarket trading, driven by the company's significant increase in net profit for the second quarter, reaching 26.5 billion kroner, equivalent to 3.55 billion euros. This marks a 32 percent rise compared to the same period last year, along with an 18 percent increase in sales of its Wegovy weight-control drug. However, the company faces intensifying competition from rival treatments, particularly those from Eli Lilly, and has warned of lower growth for its treatments in the second half of the year.